Previous 10 | Next 10 |
– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients receiving hemodialysis (SEAPORT-1) now underway (NCT062...
2024-03-08 14:45:31 ET Summary 48-week results from the phase 1/2 studies, using INZ-701 for the treatment of patients with ENPP1 Deficiency and ABCC6 Deficiency, expected in Q1 2024. Results from the phase 3 ENERGY-3 study, using INZ-701 for the treatment of patients with ENPP1 D...
2024-03-08 03:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-26 17:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, t...
2023-11-27 07:30:00 ET Summary Inozyme is a rare disease therapy developer with a lead asset, INZ-701, targeting ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 has shown safety and tolerability in trials and has the potential to improve plasma PPi levels. The ENERGY-3 trial fo...
Inozyme Pharma Inc. (INZY) is expected to report $-0.32 for Q3 2023
2023-11-07 18:04:36 ET More on Inozyme Pharma Endpoints Unzipped: Inozyme's INZ-701 Twist In The Plot Seeking Alpha’s Quant Rating on Inozyme Pharma Historical earnings data for Inozyme Pharma Financial information for Inozyme Pharma For furthe...
2023-11-07 09:57:20 ET More on Inozyme Pharma Endpoints Unzipped: Inozyme's INZ-701 Twist In The Plot Seeking Alpha’s Quant Rating on Inozyme Pharma Historical earnings data for Inozyme Pharma Financial information for Inozyme Pharma For furthe...
– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 – – Topline data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency ex...
News, Short Squeeze, Breakout and More Instantly...
Inozyme Pharma Inc. Company Name:
INZY Stock Symbol:
NASDAQ Market:
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said...
2024-04-09 08:00:07 ET Edward White from H.C. Wainwright issued a price target of $14.00 for INZY on 2024-04-09 06:36:00. The adjusted price target was set to $14.00. At the time of the announcement, INZY was trading at $5.87. INZY currently trades -24.97% versus its 52 ...
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - ...